Zhejiang Qingshanhu Science & Technology City Administration Committee Hosts China-Kazakhstan Sci-Tech Cooperation Symposium
At the symposium, representatives from both China and Kazakhstan held in-depth discussions on topics such as policy orientation, industrial demand, educational resource integration, and intelligent transportation. Akylbek Kurishbayev, President of the National Academy of Sciences directly under the President of Kazakhstan, introduced in detail the Spatial-Temporal Intelligence Laboratory, which was jointly established in February 2025 with Zhejiang University of Technology, Zhonghe Technology, and other institutions.
The laboratory adopts an integrated industry–academia–research–application model, focusing on the research and development of key technologies including intelligent early warning, smart agriculture, intelligent logistics, and new energy. It also aims to jointly cultivate digital professionals in collaboration with several universities in Kazakhstan. As part of this initiative, an unveiling ceremony for the Strategic Partner of the International College of Low-Altitude Economy under the Ministry of Industry and Information Technology was held, marking a commitment to building a strong talent pipeline for the lab's future development.
As the birthplace of the Hangzhou West Sci-Tech Innovation Corridor and the main platform of Lin'an District's 'industry-strengthening' strategy, Qingshanhu Science & Technology City has been actively advancing the integrated development of strategic emerging industries focused on new equipment, new materials, and big health. It is seizing new opportunities in the intelligent robotics sector while continuously optimizing its innovation and entrepreneurship policies and financial service infrastructure. The city has already attracted 31 research institutes, 6 national key laboratories, 511 enterprises above designated size, and 522 nationally recognized high-tech enterprises.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
SINOVAC Board of Directors Strongly Denounces Deceptive and Illegal Claims by SAIF and the Imposter Former Board
Special Meeting was validly adjourned until the appropriate court can make a final decision on the validity of the PIPE shares SAIF's "announcement" about voting results demonstrates blatant disregard for the law and the Company's bylaws and a repeated pattern of self-serving and unlawful actions by the Imposter Former Board Current Board remains the only valid board of directors of the Company and will continue to govern SINOVAC BEIJING, July 09, 2025--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading biopharmaceutical company in China, categorically rejects the recent deceptive and illegal claims by SAIF and the Imposter Former Board that it purported to "reconvene" the adjourned Special Meeting of Shareholders (the "Special Meeting") and announced sham voting results of the shareholder proposals. At the July 8, 2025 Special Meeting, SINOVAC Chairman Chiang Li validly adjourned the meeting, to preserve the integrity of the Special Meeting and protect shareholder interests, pending the resolution of litigation in Antigua related to the validity of the 11.8 million shares purportedly issued following an invalid private investment in public equity ("PIPE") to Advantech/Prime and Vivo Capital (together known as the "Dissenting Investor Group"). SINOVAC shareholders should ignore SAIF's lies. SAIF and the Imposter Former Board did NOT have the authority or any legal basis to "reconvene" the Special Meeting following the valid adjournment. SAIF's self-declaration of a final tally of shareholder votes was a complete sham. SINOVAC is evaluating its legal remedies with respect to the deceptive and unlawful conduct of SAIF and the Imposter Former Board, including with authorities in Antigua and the United States. William P. Fiske, Head of M&A and Contested Situations at Georgeson, SINOVAC's proxy solicitor, stated, "At the time of the Special Meeting, according to our preliminary voting tallies, the Company's White Proxy Card secured overwhelming support from valid shareholders for the current SINOVAC Board. Had the injunction granted by the Antigua Court not been temporarily stayed, the shareholders would have voted in favor of the current SINOVAC Board." SAIF and the Gold Proxy Card secured little support outside of the same incumbent group that has propped up the Imposter Former Board to seize control of SINOVAC and destroy value for all valid common shareholders – just as they did during the seven years that they held SINOVAC hostage. The Imposter Former Board's refusal to acknowledge the lawful adjournment of the Special Meeting and their fabrication of the meeting's outcome are wholly illegal, invalid, and reckless. The rightful SINOVAC Board remains in place and will continue to govern the Company. The Board has a duty to implement the UK Privy Council's judgment and order, which includes resolving the question of the validity of the PIPE shares. The Board will continue to fight on behalf of all SINOVAC shareholders and remains committed to its mission of restoring fairness, delivering value and protecting the rights of all valid shareholders. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ("SEC") and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law. View source version on Contacts Investor and Media Contact FGS GlobalSinovac@ Sign in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
SINOVAC Board of Directors Provides Update on Status of US$55.00 Special Cash Dividend Payment
Special cash dividend is being paid to valid common shareholders who owned SINOVAC as of the close of business on July 7, 2025 Board will continue to prioritize dividend distributions according to its previously announced policy For any questions about the dividend payment process, shareholders should contact Dividend Information Agent D.F. King at sva@ BEIJING, July 09, 2025--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the previously declared US$55.00 per common share special cash dividend is in the process of being paid to valid shareholders who owned SINOVAC shares as of the close of business on July 7, 2025. On July 8, 2025, the Paying Agent and the Transfer Agent confirmed valid SINOVAC shareholders. Those shareholders are scheduled to receive the special dividend payment as follows: For SINOVAC shareholders that are "record holders" listed on the Transfer Agent's share register, dividend checks have been prepared and will be sent via FedEx or UPS on July 9, 2025, for overnight delivery if the amount to be paid to the shareholder is under US$100 million (delivery may take longer than overnight if being sent to an address outside the United States). If the amount to be paid to a record holder is US$100 million or more, the amount will be sent via wire transfer, and the shareholder should contact the Paying Agent or Dividend Information Agent to arrange wire instructions. For SINOVAC shareholders whose shares are held through a broker, their broker must fill out a "broker letter" and deliver it to the Paying Agent in order for the dividend payment to be made to the broker. The form of broker letter was posted on the DTC website and provided to each broker by the Dividend Information Agent last week. For brokers who have already provided the broker letter to the Paying Agent, the dividend payment will be wired to the broker starting July 9, 2025. The Company has been advised that once a broker receives the wire, the beneficial owner shareholder account is typically credited by the broker that same day, but it could be the next business day if the wire is received by the broker late in the day. ADDITIONAL INFORMATION If you have questions about the dividend payment process, please contact the Dividend Information Agent: D.F. King & Co., Inc., 28 Liberty Street, 53rd Floor, New York, NY 10005, Attention: Sinovac Biotech Ltd. Special Dividend; email: sva@ with a subject line of Sinovac Biotech Ltd, Special Dividend. For more details on the misdeeds and shareholder harm caused by the Imposter Former Board and Dissenting Investor Group, visit our website If you have questions about how your vote can be counted, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S. and (646) 543-1968 outside the U.S. or via email at SinovacSpecialMeeting@ About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ("SEC") and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law. View source version on Contacts Investor and Media Contact FGS GlobalSinovac@
Bloomberg
29 minutes ago
- Bloomberg
US Tariffs Are Making Pools More Expensive, Market Leader Says
The world's largest swimming pool maker will likely hike prices for a second time this year as a result of US President Donald Trump's proposed tariffs. 'I think we'll have to raise prices somewhat due to tariffs,' Fluidra SA Chief Executive Officer Jaime Ramirez said in an interview. 'How much, I can't tell you right now, because it depends on what they announce about China in the coming weeks.'
